PRECLINICAL DRUG DEVELOPMENT: RATIONALE AND METHODSVENDITTI JM.1981; SEMIN. ONCOL.; ISSN 0093-7754; USA; DA. 1981; VOL. 8; NO 4; PP. 349-361; BIBL. 39 REF.Article

DRUG EVALUATION BRANCH PROGRAM. REPORT TO THE SCREENING CONTRACTORSVENDITTI JM.1975; CANCER CHEMOTHERAPY REP., 2; U.S.A.; DA. 1975; VOL. 5; NO 1; PP. 1-4; BIBL. 6 REF.; (SCREENERS CONF. PROC.; SILVER SPRING, MD.; 1975)Conference Paper

RESULTS OF BUTOCIN (NSC-172755) TESTING AGAINST TUMORS IN ANIMALSVENDITTI JM.1976; CANCER TREATM. REP.; U.S.A.; DA. 1976; VOL. 60; NO 3; PP. 215; BIBL. 4 REF.Article

POTENTIATION OF ACTINOMYCIN D OR ADRIAMYCIN ANTITUMOR ACTIVITY WITH DNAMARKS TA; VENDITTI JM.1976; CANCER RES.; U.S.A.; DA. 1976; VOL. 36; NO 2 PART. 1; PP. 496-504; BIBL. 30 REF.Article

THE NEW NCI SCREEN AND ITS IMPLICATIONS FOR CLINICAL EVALUATIONGOLDIN A; VENDITTI JM.1980; RECENT RESULTS CANCER RES.; DEU; DA. 1980; VOL. 70; PP. 5-20; BIBL. 28 REF.Conference Paper

RESPONSIVENESS TO CHEMOTHERAPY OF MICE WITH L1210 LYMPHOID LEUKEMIA IMPLANTED IN VARIOUS ANATOMIC SITES.WODINSKY I; MERKER PC; VENDITTI JM et al.1977; J. NATION. CANCER INST.; U.S.A.; DA. 1977; VOL. 59; NO 2; PP. 405-408; BIBL. 14 REF.Article

USEFULNESS AND LIMITATIONS OF MURINE TUMOR MODELS FOR THE IDENTIFICATION OF NEW ANTITUMOR AGENTSGOLDIN A; JOHNSON RK; VENDITTI JM et al.1980; ANTIBIOT. AND CHEMOTHERAPY; CHE; DA. 1980; VOL. 28; PP. 1-7; (39 P.); BIBL. 32 P.Article

THE ENHANCED THERAPEUTIC EFFECT OF CIS-PLATINUM (II) DIAMMINODICHLORIDE AGAINST L1210 LEUKEMIA WHEN COMBINED WITH CYCLOPHOSPHAMIDE OR 1,2-BIS (3,5-DIOXOPIPERAZINE-1-YL) PROPANE OR SEVERAL OTHER ANTITUMOR AGENTS = AUGMENTATION DE L'EFFET THERAPEUTIQUE DU DICHLORURE DE CIS DIAMINOPLATINE (II) CONTRE LA LEUCEMIE L1210 LORSQU'IL EST ASSOCIE AU CYCLOPHOSPHAMIDE OU AU BIS-(DIOXO-3,5-PIPERAZINYL-1)-1,2 PROPANE OU D'AUTRES ANTITUMORAUXWOODMAN RJ; SIRICA AE; GANG M et al.1973; CHEMOTHERAPY; SWITZ.; DA. 1973; VOL. 18; NO 3; PP. 169-183; BIBL. 17 REF.Serial Issue

SCREENING OF ANTICANCER DRUGS. V: HISTORICAL DEVELOPMENT AND CURRENT STRATEGY OF THE NATIONAL CANCER INSTITUTE DRUG DEVELOPMENT PROGRAMGOLDIN A; SCHEPARTZ SA; VENDITTI JM et al.1979; METHODS CANCER RES.; USA; DA. 1979; VOL. 16; PP. 165-245; BIBL. 4 P.Article

CALORIE RESTRICTION: EFFECT ON GROWTH OF HUMAN TUMORS HETEROTRANSPLANTED IN NUDE MICEGIOVANELLA BC; SHEPARD RC; STEHLIN JS et al.1982; J. NATL. CANCER INST.; ISSN 0027-8874; USA; DA. 1982; VOL. 68; NO 2; PP. 249-257; BIBL. 41 REF.Article

CIRCADIAN DEPENDENCE OF HOST AND TUMOR RESPONSES TO CYCLOPHOSPHAMIDE IN MICECARDOSO SS; AVERY T; VENDITTI JM et al.1978; EUROP. J. CANCER; GBR; DA. 1978; VOL. 14; NO 9; PP. 949-954; BIBL. 17 REF.Article

EFFECTIVENESS OF CLINICALLY ACTIVE ANTINEOPLASTIC DRUGS IN A SURGICAL-ADJUVANT CHEMOTHERAPY TREATMENT REGIMEN USING LEWIS LUNG (LL) CARCINOMA.MERKER PC; WODINSKY I; CANTOR ML et al.1978; INTERNATION. J. CANCER; SWITZ.; DA. 1978; VOL. 21; NO 4; PP. 482-489; ABS. FR.; BIBL. 26 REF.Article

INACTIVITY OF DL-AMYGDALIN AGAINST HUMAN BREAST AND COLON TUMOR XENOGRAFTS IN ATHYMIC (NUDE) MICE.OVEJERA AA; HOUCHENS DP; BARKER AD et al.1978; CANCER TREATM. REP.; U.S.A.; DA. 1978; VOL. 62; NO 4; PP. 576-578; BIBL. 7 REF.Article

COMBINED MODALITY THERAPY: ACTINOMYCIN D (NSC-3053) AND ALPHA -RADIATION AGAINST THE RIDGWAY OSTEOGENIC SARCOMAMERKER PC; WODINSKY I; VENDITTI JM et al.1975; CANCER CHEMOTHERAPY REP.,2; U.S.A.; DA. 1975; VOL. 5; NO 1; PP. 225-233; BIBL. 18 REF.; (SCREENERS CONF. PROC.; SILVER SPRING, MD.; 1975)Conference Paper

CURRENT RESULTS OF THE SCREENING PROGRAM AT THE DIVISION OF CANCER TREATMENT, NATIONAL CANCER INSTITUTEGOLDIN A; VENDITTI JM; MACDONALD JS et al.1981; EUR. J. CANCER; ISSN 0014-2964; GBR; DA. 1981; VOL. 17; NO 2; PP. 129-142; BIBL. 32 REF.Article

DESIGN AND EVALUATION OF COMBINATION CHEMOTHERAPY TRIALS IN EXPERIMENTAL ANIMAL TUMOR SYSTEMSCORBETT TH; GRISWOLD DP JR; WOLPERT MK et al.1979; CANCER TREATM. REP.; USA; DA. 1979; VOL. 63; NO 5; PP. 799-801; BIBL. 3 REF.Article

ADEQUACIES AND INADEQUACIES IN ASSESSING MURINE TOXICITY DATA WITH ANTINEOPLASTIC AGENTSGUARINO AM; ROZENCWEIG M; KLINE I et al.1979; CANCER RES.; USA; DA. 1979; VOL. 39; NO 6 PART. 1; PP. 2204-2210; BIBL. 28 REF.Article

EVALUATION OF ANTILEUKEMIC AGENTS IN ADVANCED LEUKEMIA L1210 IN MICE XKLINE I; GANG M; TYRER DD et al.1972; CANCER CHEMOTHERAPY REP., 2,; U.S.A.; DA. 1972; VOL. 3; NO 1; PP. 1-69; BIBL. 1P.Serial Issue

INFLUENCE OF THE STAGE OF ADVANCEMENT OF LEUKEMIA L1210 IN MICE ON THE OPTIMAL SCHEDULE OF TREATMENT OF CYTOSINE ARABINOSIDE (NSC-63878) = INFLUENCE DU STADE DE L'EVOLUTION DE LA LEUCEMIE L1210 CHEZ LA SOURIS SUR LA POSOLOGIE MAXIMALE DANS LE TRAITEMENT PAR LE CYTOSINE ARABINOSIDE (NSC 63878)KLINE I; WOODMAN RJ; GANG M et al.1972; CANCER CHEMOTHERAPY REP., 1; U.S.A.; DA. 1972; VOL. 56; NO 3; PP. 327-334; BIBL. 31REF.Serial Issue

A QUICK REFERENCE CHART ON CROSS RESISTANCE BETWEEN ANTI-CANCER AGENTSSKIPPER HE; HUTCHISON DJ; SCHABEL FM JR et al.1972; CANCER CHEMOTHERAPY REP., 1; U.S.A.; DA. 1972; VOL. 56; NO 4; PP. 493-498; BIBL. 11 REF.Serial Issue